Boston Scientific Stock Declines 072% on 93 Billion Trading Volume Ranking 67th in Market Activity

On June 6, 2025, Boston Scientific (BSX) experienced a decline of 0.72%, with a trading volume of 9.30 billion, ranking 67th in the day's market activity.

Boston Scientific's stock has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects. This upgrade reflects a positive outlook on the company's financial performance, suggesting that investors may see potential for higher returns in the near future.

Wall Street analysts have expressed optimism about Boston Scientific, recommending it as a strong addition to investment portfolios. The average brokerage recommendation (ABR) for the company is favorable, further supporting the bullish sentiment surrounding the stock.

Morgan Stanley has increased its price target for Boston Scientific from $120.00 to $125.00, assigning the company an "overweight" rating. This adjustment reflects the firm's confidence in the company's future performance and its potential for growth.